HC Wainwright Brokers Raise Earnings Estimates for AVXL

Anavex Life Sciences Corp. (NASDAQ:AVXL) – Stock analysts at HC Wainwright lifted their Q1 2025 EPS estimates for shares of Anavex Life Sciences in a research note issued to investors on Thursday, December 26th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings of ($0.17) per share for the quarter, up from their previous forecast of ($0.19). HC Wainwright has a “Buy” rating and a $42.00 price objective on the stock. The consensus estimate for Anavex Life Sciences’ current full-year earnings is ($0.55) per share. HC Wainwright also issued estimates for Anavex Life Sciences’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.21) EPS and FY2025 earnings at ($0.73) EPS.

Anavex Life Sciences (NASDAQ:AVXL) last issued its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.03.

Separately, D. Boral Capital reissued a “buy” rating and set a $46.00 target price on shares of Anavex Life Sciences in a research note on Monday, December 23rd.

Anavex Life Sciences Trading Down 8.8 %

AVXL opened at $11.04 on Monday. The company has a fifty day simple moving average of $8.29 and a 200 day simple moving average of $6.46. Anavex Life Sciences has a twelve month low of $3.25 and a twelve month high of $14.44. The firm has a market cap of $936.37 million, a price-to-earnings ratio of -22.08 and a beta of 0.73.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in AVXL. Charles Schwab Investment Management Inc. raised its stake in Anavex Life Sciences by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company’s stock worth $3,783,000 after buying an additional 14,892 shares during the period. Renaissance Technologies LLC grew its position in shares of Anavex Life Sciences by 483.8% during the 2nd quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock valued at $1,968,000 after purchasing an additional 386,537 shares in the last quarter. Nwam LLC bought a new position in Anavex Life Sciences in the third quarter valued at $5,172,000. Deerfield Management Company L.P. Series C purchased a new stake in Anavex Life Sciences during the second quarter valued at about $346,000. Finally, Private Advisor Group LLC grew its position in shares of Anavex Life Sciences by 10.3% in the 3rd quarter. Private Advisor Group LLC now owns 47,413 shares of the biotechnology company’s stock worth $269,000 after buying an additional 4,442 shares during the last quarter. 31.55% of the stock is owned by institutional investors.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.